Roman Crazzolara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roman Crazzolara has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
Gabriele Kropshofer
Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria
24 shared publicationsBenjamin Hetzer
Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria
16 shared publicationsAlexandra Haid
Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria
10 shared publications- Andreas Meryk
Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria
10 shared publications Bernhard Holzner
Department of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria
10 shared publicationsChristina Salvador
Department of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria
10 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (6) , e70616
Case Series: Can Daily Patient‐Reported Outcome Measures Be Implemented for Cancer‐Related Fatigue?
Background: Cancer‐related fatigue (CrF), a prevalent and debilitating symptom among cancer patients, remains underrecognized and unstandardized in routine oncology care. To address this, we introduced a new digital tool for daily CrF measurement and integration in routine cancer treatment. Case: This case series investigates the use of the ePROtect app for daily CrF assessment in two pediatric acute lymphoblastic leukemia (ALL) patients. Data were collected up to 2 weeks after the end of intensive therapy (before the start of maintenance) and analyzed using two questions informed by the National Comprehensive Cancer Network (NCCN), each offering five possible responses and categorizing fatigue into different subclasses. This analysis compares two 3‐year‐old girls with pre‐B ALL, one with standard risk (SR) and favorable genetics, the other one with poor therapy response and stratified to high risk (HR) treatment. The SR patient responded well to treatment, experiencing severe CrF on only 6% of the treatment days. In contrast, the HR patient required intensified treatment with multiple re‐induction phases, resulting in more frequent hospitalizations and severe CrF on 19.4% of the treatment days. CrF assessments were conducted daily for both patients, achieving 98.6% and 69.5% completion rates throughout intensive therapy, for the SR and HR patient, respectively. Conclusion: This case series illustrates the feasibility and potential suitability of our tool using PROMs for CrF assessment. Furthermore, it highlights the correlation between treatment intensity, complications, and CrF levels, underlying the importance of systematically measuring fatigue in cancer patients. Such measurement may inform future efforts to develop and refine individualized supportive care strategies.
- 23 June 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (6) , e70616
Open AccessCase Series: Can Daily Patient‐Reported Outcome Measures Be Implemented for Cancer‐Related Fatigue?
Background: Cancer‐related fatigue (CrF), a prevalent and debilitating symptom among cancer patients, remains underrecognized and unstandardized in routine oncology care. To address this, we introduced a new digital tool for daily CrF measurement and integration in routine cancer treatment. Case: This case series investigates the use of the ePROtect app for daily CrF assessment in two pediatric acute lymphoblastic leukemia (ALL) patients. Data were collected up to 2 weeks after the end of intensive therapy (before the start of maintenance) and analyzed using two questions informed by the National Comprehensive Cancer Network (NCCN), each offering five possible responses and categorizing fatigue into different subclasses. This analysis compares two 3‐year‐old girls with pre‐B ALL, one with standard risk (SR) and favorable genetics, the other one with poor therapy response and stratified to high risk (HR) treatment. The SR patient responded well to treatment, experiencing severe CrF on only 6% of the treatment days. In contrast, the HR patient required intensified treatment with multiple re‐induction phases, resulting in more frequent hospitalizations and severe CrF on 19.4% of the treatment days. CrF assessments were conducted daily for both patients, achieving 98.6% and 69.5% completion rates throughout intensive therapy, for the SR and HR patient, respectively. Conclusion: This case series illustrates the feasibility and potential suitability of our tool using PROMs for CrF assessment. Furthermore, it highlights the correlation between treatment intensity, complications, and CrF levels, underlying the importance of systematically measuring fatigue in cancer patients. Such measurement may inform future efforts to develop and refine individualized supportive care strategies.
- Open Access
- 30 October 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90, 103607
Cancer-related fatigue in children during treatment: a 5-year cohort study of daily patient-reported outcomes with clinical implications
- 30 October 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90, 103607
Open AccessCancer-related fatigue in children during treatment: a 5-year cohort study of daily patient-reported outcomes with clinical implications
- Open Access
Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland
Background: Invasive fungal diseases (IFD) pose significant challenges in paediatric oncology. Their management is complicated by limited paediatric‐specific evidence, lack of standardised protocols and variability in resources across centres. This study assessed current practices and addressed the challenges in the prevention, diagnosis and treatment of IFDs in paediatric oncology centres across Germany, Austria and Switzerland.Methods: A questionnaire was distributed to senior paediatric oncologists in 70 paediatric oncology centres across Germany, Austria and Switzerland, gathering data on centre infrastructure, infectious disease (ID) expertise, annual cumulative IFD incidence in 2023, diagnostic tools, antifungal prophylaxis, treatment and follow‐up practices for IFD. Responses were analysed descriptively.Results: Sixty‐two centres responded, with a median of 56 (IQR 40–75) new oncological diagnoses per centre; 54.8% of centres managed allogeneic HCT patients. IFDs were reported in 88.7% of centres, with a median cumulative IFD incidence of 4.6% (IQR 3.0%–5.9%). No significant association was found between cumulative IFD incidence and the number of transplants, antifungal prophylaxis protocols and availability of ID consultation services. ID consultation was available in 58.1% of centres, with 24/7 support provided in 41.7% of these centres. Larger centres more frequently had paediatric ID specialists, ID consultation services and access to therapeutic drug monitoring.Conclusions: The observed heterogeneity in mycology expertise and IFD management strategies across centres reflects the inherent complexity of IFDs and the diagnostic and therapeutic uncertainties amid limited evidence. Strengthening oncology‐ID networks and implementing digital consultation platforms may promote high‐quality, equitable care, particularly for those with fewer in‐house resources.
Open AccessApproaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland
Background: Invasive fungal diseases (IFD) pose significant challenges in paediatric oncology. Their management is complicated by limited paediatric‐specific evidence, lack of standardised protocols and variability in resources across centres. This study assessed current practices and addressed the challenges in the prevention, diagnosis and treatment of IFDs in paediatric oncology centres across Germany, Austria and Switzerland.Methods: A questionnaire was distributed to senior paediatric oncologists in 70 paediatric oncology centres across Germany, Austria and Switzerland, gathering data on centre infrastructure, infectious disease (ID) expertise, annual cumulative IFD incidence in 2023, diagnostic tools, antifungal prophylaxis, treatment and follow‐up practices for IFD. Responses were analysed descriptively.Results: Sixty‐two centres responded, with a median of 56 (IQR 40–75) new oncological diagnoses per centre; 54.8% of centres managed allogeneic HCT patients. IFDs were reported in 88.7% of centres, with a median cumulative IFD incidence of 4.6% (IQR 3.0%–5.9%). No significant association was found between cumulative IFD incidence and the number of transplants, antifungal prophylaxis protocols and availability of ID consultation services. ID consultation was available in 58.1% of centres, with 24/7 support provided in 41.7% of these centres. Larger centres more frequently had paediatric ID specialists, ID consultation services and access to therapeutic drug monitoring.Conclusions: The observed heterogeneity in mycology expertise and IFD management strategies across centres reflects the inherent complexity of IFDs and the diagnostic and therapeutic uncertainties amid limited evidence. Strengthening oncology‐ID networks and implementing digital consultation platforms may promote high‐quality, equitable care, particularly for those with fewer in‐house resources.
- Open Access
- 10 June 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (8) , 2363-2375
Adherence to daily electronic symptom screening in pediatric cancer: associations with time, location and pain
Purpose: Regularly collected patient-reported outcome measures (PROMs) can facilitate early symptom detection and improve health outcomes. This explorative analysis aimed to investigate PROM adherence and factors associated with daily PROM completion among pediatric cancer patients. Methods: We analyzed data from a prospective study at the Medical University of Innsbruck in which pediatric patients with cancer treated with chemotherapy completed daily PROMs via a web-based portal (ePROtect). We analyzed the PROM adherence during their first year of treatment descriptively and using a linear mixed model to evaluate factors associated with PROM adherence. Results: Fifty patients (42% female) with a median age of 10.7 years (IQR 7.1–15.4) were included in this analysis (analysis period 05/2020 to 05/2023). The mean adherence was 48.7% (SD 27.2), with the highest adherence during the first 30 days (77.1%). Significant predictive factors for lower adherence included time in the program (logarithmic; β = -0.093, p < 0.001) and admission to the intensive care unit (β = -0.224, p < 0.001). In contrast, inpatient stays (β = 0.035, p = 0.014) and self-reported pain (β = 0.087, p = 0.002) were significant predictors for higher PROM adherence. Occurrences of adverse events were not significantly associated with adherence. Discussion: Our findings suggest that continuous daily symptom monitoring is feasible over extended periods. PROM adherence stabilized over time despite an initial drop, with higher participation observed during inpatient stays and in weeks with self-reported pain. Future research should explore and evaluate strategies to improve adherence.
- 10 June 2025
- Published by Springer Nature in Quality of Life Research
- Vol. 34 (8) , 2363-2375
Open AccessAdherence to daily electronic symptom screening in pediatric cancer: associations with time, location and pain
Purpose: Regularly collected patient-reported outcome measures (PROMs) can facilitate early symptom detection and improve health outcomes. This explorative analysis aimed to investigate PROM adherence and factors associated with daily PROM completion among pediatric cancer patients. Methods: We analyzed data from a prospective study at the Medical University of Innsbruck in which pediatric patients with cancer treated with chemotherapy completed daily PROMs via a web-based portal (ePROtect). We analyzed the PROM adherence during their first year of treatment descriptively and using a linear mixed model to evaluate factors associated with PROM adherence. Results: Fifty patients (42% female) with a median age of 10.7 years (IQR 7.1–15.4) were included in this analysis (analysis period 05/2020 to 05/2023). The mean adherence was 48.7% (SD 27.2), with the highest adherence during the first 30 days (77.1%). Significant predictive factors for lower adherence included time in the program (logarithmic; β = -0.093, p < 0.001) and admission to the intensive care unit (β = -0.224, p < 0.001). In contrast, inpatient stays (β = 0.035, p = 0.014) and self-reported pain (β = 0.087, p = 0.002) were significant predictors for higher PROM adherence. Occurrences of adverse events were not significantly associated with adherence. Discussion: Our findings suggest that continuous daily symptom monitoring is feasible over extended periods. PROM adherence stabilized over time despite an initial drop, with higher participation observed during inpatient stays and in weeks with self-reported pain. Future research should explore and evaluate strategies to improve adherence.
- Open Access
- 6 February 2025
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (2) , e177-e185
The Phoenix Sepsis Score in Pediatric Oncology Patients With Sepsis at PICU Admission: Test of Performance in a European Multicenter Cohort, 2018–2020
Objectives: The Pediatric Sepsis Definition Task Force developed and validated a new organ dysfunction score, the Phoenix Sepsis Score (PSS), as a predictor of mortality in children with suspected or confirmed infection. The PSS showed improved performance compared with prior scores. However, the criteria were derived in a general pediatric population, in which only 10% had cancer. Given that pediatric cancer patients with sepsis have higher mortality compared with noncancer patients with sepsis, we aimed to assess the PSS in PICU patients with cancer and sepsis. Design: Retrospective multicenter cohort study. Setting: Twelve PICUs across Europe. Patients: Each PICU identified patients 18 years young or younger, with underlying malignancy and suspected or proven sepsis, and admission between January 1, 2018, and January 1, 2020. Interventions: None. Measurements and Main Results: The PSS and three other scores, including Phoenix-8, Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score, and pediatric Sequential Organ Failure Assessment (pSOFA) score, were calculated for comparison. The primary outcome was 90-day all-cause mortality. We compared score performance using area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) analyses. Among 383 patients with proven or suspected sepsis, 90-day mortality was 19.3% (74/383). We failed to identify an association between a particular score and performance for 90-day mortality. The mean (95% CI) values for the AUROC of each score was: PSS 0.66 (0.59–0.72), Phoenix-8 0.65 (0.58–0.72), PELOD-2 0.64 (0.57–0.71), and pSOFA 0.67 (0.60–0.74) and for the AUPRC of each score: PSS 0.32 (0.23–0.42), Phoenix-8 0.32 (0.23–0.42), PELOD-2 0.32 (0.22–0.43), and pSOFA 0.36 (0.26–0.46). Similar results were obtained for PICU mortality or sepsis-related PICU mortality. Conclusions: Contrary to the general PICU population, our retrospective test of the PSS in a PICU oncology dataset with suspected or proved sepsis from European PICUs, 2018–2020, failed to identify improved performance in association with mortality. This unique patient population deserves development of organ dysfunction scores that reflect organ dysfunction and mortality data specifically from these patients and will require prospective validation in future studies.
- 6 February 2025
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 26 (2) , e177-e185
Open AccessThe Phoenix Sepsis Score in Pediatric Oncology Patients With Sepsis at PICU Admission: Test of Performance in a European Multicenter Cohort, 2018–2020
Objectives: The Pediatric Sepsis Definition Task Force developed and validated a new organ dysfunction score, the Phoenix Sepsis Score (PSS), as a predictor of mortality in children with suspected or confirmed infection. The PSS showed improved performance compared with prior scores. However, the criteria were derived in a general pediatric population, in which only 10% had cancer. Given that pediatric cancer patients with sepsis have higher mortality compared with noncancer patients with sepsis, we aimed to assess the PSS in PICU patients with cancer and sepsis. Design: Retrospective multicenter cohort study. Setting: Twelve PICUs across Europe. Patients: Each PICU identified patients 18 years young or younger, with underlying malignancy and suspected or proven sepsis, and admission between January 1, 2018, and January 1, 2020. Interventions: None. Measurements and Main Results: The PSS and three other scores, including Phoenix-8, Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score, and pediatric Sequential Organ Failure Assessment (pSOFA) score, were calculated for comparison. The primary outcome was 90-day all-cause mortality. We compared score performance using area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC) analyses. Among 383 patients with proven or suspected sepsis, 90-day mortality was 19.3% (74/383). We failed to identify an association between a particular score and performance for 90-day mortality. The mean (95% CI) values for the AUROC of each score was: PSS 0.66 (0.59–0.72), Phoenix-8 0.65 (0.58–0.72), PELOD-2 0.64 (0.57–0.71), and pSOFA 0.67 (0.60–0.74) and for the AUPRC of each score: PSS 0.32 (0.23–0.42), Phoenix-8 0.32 (0.23–0.42), PELOD-2 0.32 (0.22–0.43), and pSOFA 0.36 (0.26–0.46). Similar results were obtained for PICU mortality or sepsis-related PICU mortality. Conclusions: Contrary to the general PICU population, our retrospective test of the PSS in a PICU oncology dataset with suspected or proved sepsis from European PICUs, 2018–2020, failed to identify improved performance in association with mortality. This unique patient population deserves development of organ dysfunction scores that reflect organ dysfunction and mortality data specifically from these patients and will require prospective validation in future studies.
- Open Access
- 12 November 2024
- Published by Springer Nature in Discover Health Systems
- Vol. 3 (1) , 1-8
Feasibility of daily symptom-reporting by caregivers during induction treatment for pediatric cancer–an observational cohort study
- 12 November 2024
- Published by Springer Nature in Discover Health Systems
- Vol. 3 (1) , 1-8
Open AccessFeasibility of daily symptom-reporting by caregivers during induction treatment for pediatric cancer–an observational cohort study
- Open Access
- 9 November 2024
- Published by Wiley in International Journal of Cancer
- Vol. 156 (6) , 1247-1255
Pioneering sustainable treatment delivery in childhood leukemia through synchronous telemedicine—A pilot study
Cancer care places a heavy economic burden on families and health systems, driven by high treatment costs, lengthy hospital stays, and the necessity for extensive travel to specialized facilities. To address this challenge, an integrated health care network (IHCN) was implemented for maintenance treatment in acute leukemia. The IHCN encompassed outpatient services provided by local physicians and synchronous telemedicine consultation with pediatric oncologists. This study included twenty‐two pediatric patients (eleven [50.0%] females; twenty [90.9%] with B‐ALL and two [9.1%] with AML). The IHCN was offered to all rural patients (n = 17) with a one‐way driving distance more than 30 km, while urban patients (n = 5) received regular cancer care. Throughout the study, rural patients had a total of 510 routine clinical visits, with 367 (72%) conducted through the IHCN. Physical examinations revealed similar frequency of new abnormal findings for urban and rural patients (22.4% vs. 17.8%; p = .31). Laboratory tests indicated no significant difference in the frequency of abnormal values for various parameters between both groups. Similarly, there was no discrepancy of drug modifications or interruption in maintenance therapy between the two settings (p = .85). Moreover, patients' health‐related quality of life remained within the normative range, and user satisfaction with the IHCN was notably high. The implementation of the IHCN resulted in savings of 70,158 km, 950 h of travel, and 12,277 kg CO2 emissions. This pilot study underscores the efficacy of a telemedicine‐based IHCN, ensuring safety, quality of care, cost reduction, and satisfaction for both families and health care providers in pediatric leukemia management.
- 9 November 2024
- Published by Wiley in International Journal of Cancer
- Vol. 156 (6) , 1247-1255
Open AccessPioneering sustainable treatment delivery in childhood leukemia through synchronous telemedicine—A pilot study
Cancer care places a heavy economic burden on families and health systems, driven by high treatment costs, lengthy hospital stays, and the necessity for extensive travel to specialized facilities. To address this challenge, an integrated health care network (IHCN) was implemented for maintenance treatment in acute leukemia. The IHCN encompassed outpatient services provided by local physicians and synchronous telemedicine consultation with pediatric oncologists. This study included twenty‐two pediatric patients (eleven [50.0%] females; twenty [90.9%] with B‐ALL and two [9.1%] with AML). The IHCN was offered to all rural patients (n = 17) with a one‐way driving distance more than 30 km, while urban patients (n = 5) received regular cancer care. Throughout the study, rural patients had a total of 510 routine clinical visits, with 367 (72%) conducted through the IHCN. Physical examinations revealed similar frequency of new abnormal findings for urban and rural patients (22.4% vs. 17.8%; p = .31). Laboratory tests indicated no significant difference in the frequency of abnormal values for various parameters between both groups. Similarly, there was no discrepancy of drug modifications or interruption in maintenance therapy between the two settings (p = .85). Moreover, patients' health‐related quality of life remained within the normative range, and user satisfaction with the IHCN was notably high. The implementation of the IHCN resulted in savings of 70,158 km, 950 h of travel, and 12,277 kg CO2 emissions. This pilot study underscores the efficacy of a telemedicine‐based IHCN, ensuring safety, quality of care, cost reduction, and satisfaction for both families and health care providers in pediatric leukemia management.
- Open Access
- 21 September 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (12) , 776.e1-776.e7
Integration of Daily Patient-Reported Outcome Measures in Pediatric Stem Cell Transplantation
- 21 September 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (12) , 776.e1-776.e7
Open AccessIntegration of Daily Patient-Reported Outcome Measures in Pediatric Stem Cell Transplantation
- Open Access
Recommendations for Nutritional Supplementation in Pediatric Oncology: A Compilation of the Facts
Background: As one of the few modifiable risk factors, the importance of dietary patterns for both disease prevention and treatment outcome in pediatric oncology has gained increasing popularity. Malnutrition is associated with lower survival rates, tolerance to treatment, and quality of life. Yet, especially in children with malignancies, nutritional deterioration is common, and pediatric cancer patients often present with inadequate intake of micro- and macronutrients alike. Despite the reported widespread use of dietary supplements, few empirical data provide a basis for clinical recommendations, and evidence for their efficacy is inconsistent. Current literature lacks a systematic approach as to how and which supplements should be recommended for specific patients, types of cancer, or during specific treatments. The aim of this review is to highlight the role of the most frequently used nutrients in pediatric malignant diseases and to give a practical guide based on current scientific evidence. Methods: A comprehensive literature search was conducted on PubMed through April 2023 to select meta-analyses, systematic reviews, observational studies, and individual randomized controlled trials (RCTs) of macro- and micronutrient supplementation in pediatric oncology. The search strategy included the following medical subject headings (MeSH) and keywords: “childhood cancer”, “pediatric oncology”, “nutritional status”, “dietary supplements”, “vitamins”, “micronutrients”, “calcium”, “magnesium”, “vitamin D”, “zinc” “glutamine”, “selen”, and “omega-3 fatty acids”. The reference lists of all relevant articles were screened to include potentially pertinent studies. Results: The present review provides a comprehensive and updated overview of the latest evidence about the role of nutrition and diet in pediatric oncology, also focusing on different nutritional interventions available for the management of the disease. We summarize evidence about the importance of adequate nutrition in childhood cancer and the role of several micronutrients and critically interpret the findings. Possible effects and benefits of supplementation during chemotherapy are discussed, as are strategies for primary and secondary prevention. Conclusions: We here describe the obvious benefits of dietary supplementation for childhood cancer. Further large-scale clinical trials are required to verify the impacts of deficiencies and the possible benefits of supplementation and optimal dosages. (337 words).
Open AccessRecommendations for Nutritional Supplementation in Pediatric Oncology: A Compilation of the Facts
Background: As one of the few modifiable risk factors, the importance of dietary patterns for both disease prevention and treatment outcome in pediatric oncology has gained increasing popularity. Malnutrition is associated with lower survival rates, tolerance to treatment, and quality of life. Yet, especially in children with malignancies, nutritional deterioration is common, and pediatric cancer patients often present with inadequate intake of micro- and macronutrients alike. Despite the reported widespread use of dietary supplements, few empirical data provide a basis for clinical recommendations, and evidence for their efficacy is inconsistent. Current literature lacks a systematic approach as to how and which supplements should be recommended for specific patients, types of cancer, or during specific treatments. The aim of this review is to highlight the role of the most frequently used nutrients in pediatric malignant diseases and to give a practical guide based on current scientific evidence. Methods: A comprehensive literature search was conducted on PubMed through April 2023 to select meta-analyses, systematic reviews, observational studies, and individual randomized controlled trials (RCTs) of macro- and micronutrient supplementation in pediatric oncology. The search strategy included the following medical subject headings (MeSH) and keywords: “childhood cancer”, “pediatric oncology”, “nutritional status”, “dietary supplements”, “vitamins”, “micronutrients”, “calcium”, “magnesium”, “vitamin D”, “zinc” “glutamine”, “selen”, and “omega-3 fatty acids”. The reference lists of all relevant articles were screened to include potentially pertinent studies. Results: The present review provides a comprehensive and updated overview of the latest evidence about the role of nutrition and diet in pediatric oncology, also focusing on different nutritional interventions available for the management of the disease. We summarize evidence about the importance of adequate nutrition in childhood cancer and the role of several micronutrients and critically interpret the findings. Possible effects and benefits of supplementation during chemotherapy are discussed, as are strategies for primary and secondary prevention. Conclusions: We here describe the obvious benefits of dietary supplementation for childhood cancer. Further large-scale clinical trials are required to verify the impacts of deficiencies and the possible benefits of supplementation and optimal dosages. (337 words).
- Open Access
- 19 June 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30498
Can virtual care reduce treatment burden in pediatric leukemia? A retrospective cost analysis
We conducted a retrospective analysis to determine the potential reduction in treatment burden through the expansion of virtual care among children with leukemia (n = 152). Patients living in urban areas traveled median distances of 1555 km compared with 7536 km for patients living in rural areas (p < .05). For the latter group, a median reduction in travel distance of 3560 km (interquartile range [IQR], 2136–5787 km), travel time of 51 h (IQR, 26–78 h), and CO2 emissions of 623 kg (IQR, 374–1013 kg) was estimated, if every second visit was replaced by video consultations.
- 19 June 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (9) , e30498
Open AccessCan virtual care reduce treatment burden in pediatric leukemia? A retrospective cost analysis
We conducted a retrospective analysis to determine the potential reduction in treatment burden through the expansion of virtual care among children with leukemia (n = 152). Patients living in urban areas traveled median distances of 1555 km compared with 7536 km for patients living in rural areas (p < .05). For the latter group, a median reduction in travel distance of 3560 km (interquartile range [IQR], 2136–5787 km), travel time of 51 h (IQR, 26–78 h), and CO2 emissions of 623 kg (IQR, 374–1013 kg) was estimated, if every second visit was replaced by video consultations.